These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098 [TBL] [Abstract][Full Text] [Related]
5. [Pompe disease treated with enzyme replacement therapy in pregnancy]. Grosz Z; Várdi KV; Molnár JM Ideggyogy Sz; 2020 Sep; 73(9-10):339-344. PubMed ID: 33035415 [TBL] [Abstract][Full Text] [Related]
6. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Lipinski SE; Lipinski MJ; Burnette A; Platts-Mills TA; Wilson WG Mol Genet Metab; 2009 Nov; 98(3):319-21. PubMed ID: 19640753 [TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy. Oliveira Santos M; Evangelista T; Conceição I Neuromuscul Disord; 2018 Nov; 28(11):965-968. PubMed ID: 30314719 [TBL] [Abstract][Full Text] [Related]
8. First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease. de Vries JM; Brugma JD; Ozkan L; Steegers EA; Reuser AJ; van Doorn PA; van der Ploeg AT Mol Genet Metab; 2011 Dec; 104(4):552-5. PubMed ID: 21967859 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983 [TBL] [Abstract][Full Text] [Related]
10. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Lacaná E; Yao LP; Pariser AR; Rosenberg AS Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234 [TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT; Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310 [TBL] [Abstract][Full Text] [Related]
12. Alglucosidase alfa and Pompe disease: still going strong? Lipinski SE Mol Genet Metab; 2012 Nov; 107(3):245-6. PubMed ID: 23034445 [No Abstract] [Full Text] [Related]